News
RNAC
8.76
-1.02%
-0.09
Weekly Report: what happened at RNAC last week (0803-0807)?
Weekly Report · 19h ago
Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)
TipRanks · 3d ago
Cartesian Therapeutics: Late-Stage Descartes-08 De-Risking and 2027 Data Wave Underpin Van Buren’s Buy Rating
TipRanks · 3d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 3d ago
Buy Rating Reiterated on Strong Cash Runway and Near‑Term Clinical Catalysts; $40 Price Target Maintained
TipRanks · 4d ago
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Benzinga · 4d ago
*Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC
Dow Jones · 4d ago
*Cartesian Therapeutics 2Q EPS 46c >RNAC
Dow Jones · 4d ago
Press Release: Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 4d ago
Weekly Report: what happened at RNAC last week (0727-0731)?
Weekly Report · 08/03 09:19
Weekly Report: what happened at RNAC last week (0720-0724)?
Weekly Report · 07/27 09:20
Weekly Report: what happened at RNAC last week (0713-0717)?
Weekly Report · 07/20 09:19
Weekly Report: what happened at RNAC last week (0706-0710)?
Weekly Report · 07/13 09:19
Weekly Report: what happened at RNAC last week (0629-0703)?
Weekly Report · 07/06 09:20
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 07/02 06:05
BTIG’s top small and mid-cap stocks for H2, ranked by SA Quant
Seeking Alpha · 07/01 16:32
Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst
TipRanks · 07/01 11:35
New Strong Sell Stocks for July 1st
NASDAQ · 07/01 07:33
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
NASDAQ · 06/30 12:00
Weekly Report: what happened at RNAC last week (0622-0626)?
Weekly Report · 06/29 09:19
More
Webull provides a variety of real-time RNAC stock news. You can receive the latest news about Cartesian through multiple platforms. This information may help you make smarter investment decisions.
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.